Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keverprazan + amoxicillin dual therapy versus susceptibility-guided quadruple therapy for Helicobacter pylori rescue treatment
ChiCTR2500095818Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of keverprazan and amoxicillin in Helicobacter pylori infection (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Helicobacter pylori eradication rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
keverprazanamoxicillin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2500095818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095818.